ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

October 31, 2009

Conditions
HIV-1
Interventions
DRUG

Truvada + Kaletra

Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.

DRUG

Kivexa + Kaletra

Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.

Trial Locations (4)

1220

Gilead Sciences, Vienna

Unknown

Gilead Sciences, Munich

Gilead Sciences, Milan

Gilead Sciences, Madrid

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY